Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alefacept - Astellas Pharma

Next Previous
X
Search
Drug Profile

Alefacept - Astellas Pharma

Alternative Names: Amevive; ASP 0485; BG 9273; BG 9712; Human LFA-3/IgG fusion protein; LFA 3 TIP; Recombinant LFA-3/IgG1 human fusion protein

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Michigan Medical School
  • Developer Astellas Pharma; Cleveland Clinic
  • Class Antipsoriatics; Recombinant fusion proteins
  • Mechanism of Action CD2 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Psoriasis
  • No development reported Aplastic anaemia
  • Discontinued Psoriatic arthritis; Transplant rejection

Most Recent Events

  • 08 Apr 2021 No development reported - Phase-I/II for Aplastic anaemia (Treatment-experienced) in USA (IV) (NCT01267643)
  • 24 Jan 2018 Astellas Pharma terminates a phase I/II trial due to the study drug not available at the time in Aplastic anaemia (Treatment-experienced) in USA (IV) (NCT01267643)
  • 15 Mar 2012 Astellas Pharma completes its Phase-II trial for Psoriasis in USA, Bulgaria and Latvia (NCT00808223)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top